Overview


According to FutureWise analysis the market for biosimulation is expected to register a CAGR of 16.10% from 2023-2031.

Bio-simulation is a distinct part of systems biology, which gives information about complex biological systems in disease and health. The bio-simulation is also referred to as in-silico biology, which means biological experiments have to carry out in the computer. It is an entirely new concept in the drug development industry, which relies on expressing the biological systems with mathematical expressions, thus, capturing biological elements and their relationships, and simulating the behaviour of certain systems in different situations. There are different types of bio-simulation approaches are available which gives outcome based on the complexity of biosystem and the disease- drug target. It credits the reduction and replacement of animal and human experimentations as well as improves the knowledge of how patients need to administer medicine.

Biosimulation has a huge demand for drug development for mimicking disease indication. It is used to simulate the disease indication and decrease the effort of research. Increasing attrition rates of drug development have increased the dependence of research companies on simulation techniques for minimizing capital investments. Additionally, the rapid advancement of technologies has integrated the biosimulation process in clinical trials and offers complete automation. Biosimulation techniques also minimize human errors and increase the efficiency of the development process. Further, it also decreases the development time and speeds up the whole drug discovery process. All these factors led to robust growth of the market during the forecast period. Global Biosimulation market is expected to witness a high adoption rate due to increasing awareness of simulation techniques among the drug developing companies.

North America market is expected to account major share in the global market due to high R D investments of top drug manufacturers. It was followed by the European region and it also accounts significant share over the forecast period. It is expected to witness high growth rate over the forecast period. Both North America and Europe market is expected to remain dominant in the global market over the forecast period. The Asia Pacific, Latin America and Rest of the world market are expected to account a small fraction of market share due to less adoption.

  • Certara
  • Simulations Plus
  • Dassault Systèmes
  • Schrödinger
  • ACD/Labs
  • Chemical Computing Group
  • Physiomics
  • Evidera
  • In silico biosciences
  • INOSIM Software
  • Insilico Biotechnology
  • LeadInvent Technologies
  • Rosa
  • Nuventra Pharma
  • Genedata.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product and Service

  • Software
    • Molecular Modeling and Simulation Software
    • PBPK Modeling and Simulation Software
    • PK/PD Modeling and Simulation Software
    • Trial Design Software
    • Toxicity Prediction Software
    • Other Biosimulation Software
  • Services
    • In-house Services
    • Contract Services

By Application

  • Drug Development
  • Drug Discovery
  • Other Applications

By Delivery Model

  • Subscription Models
  • Ownership Models

By End User

  • Pharmaceutical and Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Regulatory Authorities
  • Other End Users

By Region

  • Europe
  • North America
  • APAC
  • Latin America
  • Rest of World

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global market By product and service, By application, By delivery model, By end user and By region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data From Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Biosimulation Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Biosimulation Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Biosimulation Market, By Product and Services Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Software
         1.1. Molecular Modeling and Simulation Software
         1.2. PBPK Modeling and Simulation Software
         1.3. PK/PD Modeling and Simulation Software
         1.4. Trial Design Software
         1.5. Toxicity Prediction Software
         1.6. Other Biosimulation Software
        2. Services
         2.1. In-house Services
         2.2. Contract Services

  • 8.   Global Biosimulation Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Drug Development
        2. Drug Discovery
        3. Other Applications

  • 9.  Global Biosimulation Market, By Delivery Model Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Subscription Models
        2. Ownership Models

  • 10.   Global Biosimulation Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical and Biotechnology Companies
        2. Research Institutes
        3. Contract Research Organizations
        4. Regulatory Authorities
        5. Other End Users

  • 11.   North America Biosimulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) along with expected regulatory needs
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Europe Biosimulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Biosimulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) - along with expected regulatory needs
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Latin America Biosimulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Rest of World Biosimulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Certara
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Simulation Plus
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Dassault Systèmes
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Schrödinger
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ACD/Labs
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Chemical Computing Group
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
         7. Physiomics
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Evidera
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. In silico biosciences
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. INOSIM Software
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Insilico Biotechnology
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. LeadInvent Technologies
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Rosa
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Nuventra Pharma
         14.1. Company Overview
         14.2. Product Portfolio
         14..3. SWOT Analysis
         14..4. Financial Overview
         14..5. Strategic Overview
        15. Genedata.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   FutureWise SME key takeaway points for Client
Partner

Our Clients